Exhibit 10.42

Execution Version

JOINDER AGREEMENT

This Joinder Agreement is dated as of January 22, 2015 (this “Agreement”), by
and among each of the financial institutions set forth on Schedule A annexed
hereto (each a “New Term Loan Lender” and collectively the “New Term Loan
Lenders”), Valeant Pharmaceuticals International, Inc., a corporation continued
under the laws of the Province of British Columbia (“Borrower”), the undersigned
subsidiaries of Borrower and Barclays Bank PLC (“Barclays”), as Administrative
Agent and Collateral Agent.

RECITALS:

WHEREAS, reference is hereby made to the Third Amended and Restated Credit and
Guaranty Agreement, dated as of February 13, 2012, as amended by Amendment
No. 1, dated as of March 6, 2012, by Amendment No. 2, dated as of September 10,
2012, by Amendment No. 3, dated as of January 24, 2013, by Amendment No. 4,
dated as of February 21, 2013, by Amendment No. 5, dated as of June 6, 2013, by
Amendment No. 6, dated as of June 26, 2013, by Amendment No. 7, dated as of
September 17, 2013, by Amendment No. 8, dated as of December 20, 2013, by the
Successor Agent Agreement and Amendment No. 9, dated as of January 8, 2015, as
further supplemented by the Joinder Agreement, dated as of June 14, 2012, by the
Joinder Agreement, dated as of July 9, 2012, by the Joinder Agreement, dated as
of September 11, 2012, by the Joinder Agreement dated as of October 2, 2012, by
the Joinder Agreement, dated as of December 11, 2012, by the Joinder Agreements,
each dated as of August 5, 2013, and by the Joinder Agreements, each dated as of
February 6, 2014 (as it may be amended, restated, replaced, supplemented or
otherwise modified from time to time, the “Credit Agreement”; the terms defined
therein and not otherwise defined herein being used herein as therein defined),
among Borrower, certain Subsidiaries of Borrower, as Guarantors, the Lenders
party thereto from time to time, Goldman Sachs Lending Partners LLC (“GSLP”),
J.P. Morgan Securities LLC and Morgan Stanley Senior Funding, Inc. (“Morgan
Stanley”), as Joint Lead Arrangers and Joint Bookrunners, JPMorgan Chase Bank,
N.A. (“JPMorgan”) and Morgan Stanley, as Co-Syndication Agents, JPMorgan, as
Issuing Bank, Barclays (as successor to GSLP), as Administrative Agent and
Collateral Agent, and the other Agents party thereto;

WHEREAS, subject to the terms and conditions of the Credit Agreement, Borrower
may obtain New Revolving Loan Commitments and/or New Term Loan Commitments by
entering into one or more Joinder Agreements with the New Term Loan Lenders;

WHEREAS, pursuant to Section 2.25 of the Credit Agreement, the Credit Agreement
may, without the consent of any other Lenders, be amended as may be necessary or
appropriate, in the opinion of the Administrative Agent, to give effect to the
provisions of Section 2.25 of the Credit Agreement; and

WHEREAS, the Borrower may, in its sole discretion, use the proceeds of the
Additional Series A-3 Tranche A Term Loans (as defined below) for general
corporate purposes, including repayment of outstanding Indebtedness of the
Borrower.

NOW, THEREFORE, in consideration of the premises and agreements, provisions and
covenants herein contained, the parties hereto agree as follows:

Each New Term Loan Lender (i) confirms that it has received a copy of the Credit
Agreement and the other Credit Documents, together with copies of the financial
statements referred to

--------------------------------------------------------------------------------

therein and such other documents and information as it has deemed appropriate to
make its own credit analysis and decision to enter into this Agreement;
(ii) agrees that it will, independently and without reliance upon the
Administrative Agent or any other Lender or Agent and based on such documents
and information as it shall deem appropriate at the time, continue to make its
own credit decisions in taking or not taking action under the Credit Agreement;
(iii) appoints and authorizes Administrative Agent and each other Agent to take
such action as agent on its behalf and to exercise such powers under the Credit
Agreement and the other Credit Documents as are delegated to Administrative
Agent or such other Agent, as the case may be, by the terms thereof, together
with such powers as are reasonably incidental thereto; and (iv) agrees that it
will perform in accordance with their terms all of the obligations which by the
terms of the Credit Agreement are required to be performed by it as a Lender.

Each New Term Loan Lender hereby commits to provide its respective New Term Loan
Commitment (each an “Additional Series A-3 Tranche A Term Loan Commitment”) as
set forth on Schedule A annexed hereto, on the terms and subject to the
conditions set forth below:

 

1. Additional Series A-3 Tranche A Term Loan Commitments. The terms and
provisions of the New Term Loans made pursuant to this Agreement (the
“Additional Series A-3 Tranche A Term Loans” and each an “Additional Series A-3
Tranche A Term Loan”) shall be identical to, and constitute, Series A-3 Tranche
A Term Loans for all purposes under the Credit Agreement. The Additional Series
A-3 Tranche A Term Loan Commitments and Additional Series A-3 Tranche A Term
Loans made pursuant thereto shall be subject to the provisions of the Credit
Agreement and the other Credit Documents, and shall constitute “Tranche A Term
Loan Exposure” and “Tranche A Term Loans”, respectively, thereunder.

 

2. Principal Payments. Borrower shall make principal payments on the Additional
Series A-3 Tranche A Term Loans beginning March 31, 2016 in installments on the
dates and in the amounts equal to the percentage which are identical to those
with respect to Series A-3 Tranche A Term Loans which, for the avoidance of
doubt, are set forth below including with respect to the Additional Series A-3
Tranche A Term Loans:

 

Amortization Date

   Additional Series A-3 Tranche A Term
Loan Installments  

March 31, 2015

     —     

June 30, 2015

     —     

September 30, 2015

     —     

December 31, 2015

     —     

March 31, 2016

     5.42%   

June 30, 2016

     5.42%   

September 30, 2016

     5.42%   

December 31, 2016

     5.42%   

March 31, 2017

     5.42%   

June 30, 2017

     5.42%   

September 30, 2017

     5.42%   

December 31, 2017

     5.42%   

March 31, 2018

     5.42%   

June 30, 2018

     5.42%   

September 30, 2018

     5.42%   

Series A-3 Tranche A Term Loan Maturity Date

     Remaining Balance   

 

-2-

--------------------------------------------------------------------------------

3. Closing Fee. Borrower agrees to pay on the Additional Series A-3 Tranche A
Term Loan Funding Date (as defined below) to Administrative Agent, for the
account of each New Term Loan Lender party to this Agreement, as fee
compensation for the commitment of such New Term Loan Lender’s Additional Series
A-3 Tranche A Loan Commitments, a closing fee in an amount equal to 0.15 % of
the aggregate principal amount of such New Term Loan Lender’s allocated
Additional Series A-3 Tranche A Term Loan Commitments which are actually funded
on the Additional Series A-3 Tranche A Term Loan Funding Date.

 

4. Proposed Borrowing. In accordance with Section 2.25 of the Credit Agreement,
Borrower has previously delivered to Administrative Agent an executed Funding
Notice for Additional Series A-3 Tranche A Term Loans, requesting a proposed
borrowing in the principal amount of up to $250,000,000 (the “Proposed
Borrowing”) on the date hereof (the “Additional Series A-3 Tranche A Term Loan
Funding Date”). Each New Term Loan Lender shall make its Additional Series A-3
Tranche A Term Loan available to Administrative Agent not later than 11:00 a.m.
(New York City time) on the date hereof, by wire transfer of same day funds in
Dollars at the Principal Office designated by Administrative Agent. Promptly
upon receipt thereof, Administrative Agent shall make the proceeds of the
Additional Series A-3 Tranche A Term Loans available to Borrower on the date
hereof by causing an amount of same day funds in Dollars equal to the proceeds
of all such loans received by Administrative Agent from New Term Loan Lenders to
be credited to the account of Borrower, at the Principal Office designated by
Administrative Agent or to such other account as may be designated in writing to
Administrative Agent by Borrower.

 

5. New Lenders. Each New Term Loan Lender (other than any New Term Loan Lender
that, immediately prior to the execution of this Agreement, is a “Lender” under
the Credit Agreement) acknowledges and agrees that upon its execution of this
Agreement its Additional Series A-3 Tranche A Term Loan Commitments shall be
effective and that such New Term Loan Lender shall become a “Lender” under, and
for all purposes of, the Credit Agreement and the other Credit Documents, and
shall be subject to and bound by the terms thereof, and shall perform all the
obligations of and shall have all rights of a Lender thereunder.

 

6. Credit Agreement Governs. Additional Series A-3 Tranche A Term Loans shall be
subject to the provisions of the Credit Agreement and the other Credit
Documents, except as set forth in this Agreement, and shall constitute Tranche A
Term Loans thereunder.

 

7. Borrower’s Certifications. By its execution of this Agreement, the
undersigned officer, to the best of his or her knowledge, and Borrower hereby
certify that:

 

  i. The representations and warranties contained in the Credit Agreement and
the other Credit Documents are true and correct in all material respects on and
as of the date hereof to the same extent as though made on and as of the date
hereof, except to the extent such representations and warranties specifically
relate to an earlier date, in which case such representations and warranties
were true and correct in all material respects on and as of such earlier date;

 

  ii. No event has occurred and is continuing or would result from the
consummation of the Proposed Borrowing contemplated hereby that would constitute
a Default or an Event of Default; and

 

  iii. Borrower has performed in all material respects all agreements and
satisfied all conditions which the Credit Agreement provides shall be performed
or satisfied by it on or before the date hereof in connection with the Proposed
Borrowing.

 

-3-

--------------------------------------------------------------------------------

8. Borrower Covenants. By its execution of this Agreement, Borrower hereby
covenants that:

 

  i. Borrower shall deliver or cause to be delivered, on or before the
Additional Series A-3 Tranche A Term Loan Funding Date, the following legal
opinions and documents: originally executed copies of the favorable written
opinions of (a) Skadden, Arps, Slate, Meagher & Flom LLP, U.S. counsel and
special France counsel to the Credit Parties, (b) Chancery Chambers, special
Barbados counsel to the Credit Parties, (c) Norton Rose Fulbright Canada LLP,
special Canada counsel to the Credit Parties, (d) Baker & McKenzie, special
Luxembourg counsel to the Credit Parties, (e) Conyers Dill & Pearman Limited,
special Bermuda counsel to the Credit Parties, (f) Arthur Cox, special Ireland
counsel to the Credit Parties, (g) Venable LLP, special Maryland counsel to the
Credit Parties, (h) Souza, Cescon, Barrieu & Flesch Advogados, special Brazil
counsel to the Credit Parties, (i) Squire Sanders Święcicki Krześniak sp.k.,
special Poland counsel to the Credit Parties, (j) Tark Grunte Sutkiene, special
Lithuania counsel to the Credit Parties, (k) White & Case LLP, special France
counsel to the Administrative Agent, (l) Allen & Overy LLP, special Netherlands
counsel to the Administrative Agent, (m) Rajah & Tann LLP, special Singapore
counsel to the Credit Parties, (n) Stamford Law Corporation, special Singapore
counsel to the Administrative Agent and (o) Fluxmans Inc., special South Africa
counsel to the Credit Parties, together with all other legal opinions and other
documents reasonably requested by Administrative Agent in connection with this
Agreement.

 

9. Eligible Assignee. By its execution of this Agreement, each New Term Loan
Lender (other than any New Term Loan Lender that, immediately prior to the
execution of this Agreement, is a “Lender” under the Credit Agreement)
represents and warrants that it is an Eligible Assignee.

 

10. Notice. For purposes of the Credit Agreement, the initial notice address of
each New Term Loan Lender shall be as set forth below its signature below.

 

11. Non-U.S. Lenders. For each New Term Loan Lender that is a Non-U.S. Lender,
delivered herewith to Administrative Agent are such forms, certificates or other
evidence with respect to United States federal income tax withholding matters as
such New Term Loan Lender may be required to deliver to Administrative Agent
pursuant to subsection 2.20(d) of the Credit Agreement.

 

12. Recordation of the New Loans. Upon execution and delivery hereof,
Administrative Agent will record in the Register the Additional Series A-3
Tranche A Term Loans made by New Term Loan Lenders pursuant hereto as being of
the same Class as the Series A-3 Tranche A Term Loans.

 

13. Reaffirmation.

 

  i. Each Credit Party hereby expressly acknowledges the terms of this Agreement
and reaffirms, as of the date hereof, the covenants and agreements contained in
each Credit Document to which it is a party, including, in each case, such
covenants and agreements as in effect immediately after giving effect to this
Agreement and the transactions contemplated hereby.

 

  ii.

Each Credit Party, by its signature below, hereby affirms and confirms (a) its
obligations under each of the Credit Documents to which it is a party, and
(b) the pledge of and/or grant of a security interest or hypothec in its assets
as Collateral to secure such Obligations, all as provided in the Collateral
Documents as originally

 

-4-

--------------------------------------------------------------------------------

  executed, and acknowledges and agrees that such guarantee, pledge and/or grant
continue in full force and effect in respect of, and to secure, such Obligations
under the Credit Agreement and the other Credit Documents.

 

  ii. Each Credit Party acknowledges and agrees that each of the Credit
Documents in existence as of the date hereof shall be henceforth read and
construed in accordance with and so as to give full force and effect to the
ratifications, confirmations, acknowledgements and agreements made herein.

 

14. Amendment, Modification and Waiver. This Agreement may not be amended,
modified or waived except by an instrument or instruments in writing signed and
delivered on behalf of each of the parties hereto.

 

15. Entire Agreement. This Agreement, the Credit Agreement and the other Credit
Documents constitute the entire agreement among the parties with respect to the
subject matter hereof and thereof and supersede all other prior agreements and
understandings, both written and verbal, among the parties or any of them with
respect to the subject matter hereof. It is understood and agreed that each
reference in each Credit Document to the Credit Agreement, whether direct or
indirect, shall hereafter be deemed to be a reference to the Credit Agreement as
amended and supplemented hereby and that this Agreement is a Credit Document.

 

16. GOVERNING LAW. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES
HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

 

17. Severability. Any term or provision of this Agreement which is invalid or
unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective
to the extent of such invalidity or unenforceability without rendering invalid
or unenforceable the remaining terms and provisions of this Agreement or
affecting the validity or enforceability of any of the terms or provisions of
this Agreement in any other jurisdiction. If any provision of this Agreement is
so broad as to be unenforceable, the provision shall be interpreted to be only
so broad as would be enforceable.

 

18. Counterparts. This Agreement may be executed in counterparts, each of which
shall be deemed to be an original, but all of which shall constitute one and the
same agreement.

[Remainder of page intentionally left blank]

 

-5-

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized
officer to execute and deliver this Agreement as of the date first written
above.

 

BARCLAYS BANK PLC, as a “New Term Loan Lender” By:

    /s/ Christine Aharonian

Name: Christine Aharonian Title: Vice President Notice Address: 745 Seventh
Avenue, New York, NY 10019 Attention: Christine Aharonian Telephone: 212 320
9943 Facsimile: 212 52605515

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

JPMORGAN CHASE BANK, N.A., TORONTO BRANCH, as a “New Term Loan Lender” By:

    /s/ Michael N. Tam

Name: Michael N. Tam Title: Senior Vice President Notice Address: Attention:
Telephone: Facsimile:

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

MORGAN STANLEY BANK, N.A., as a “New Term Loan Lender” By:

    /s/ Michael King

Name: Michael King Title: Authorized Signatory Notice Address: Morgan Stanley
Loan Servicing 1300 Thames Street Wharf, 4th floor Baltimore, MD 21231
Telephone: 443 627 4335

Facsimile: 718 233 2140

msloanservicing@morganstanley.com

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

SUNTRUST BANK, as a “New Term Loan Lender” By:

    /s/ Katherine Bass

Name: Katherine Bass Title: Director Notice Address: Attention: Telephone:
Facsimile:

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

THE BANK OF TOKYO-MITSUBISHI UFJ, LTD., as a “New Term Loan Lender” By:

    /s/ Scott O’Connell

Name: Scott O’Connell Title: Director Notice Address: 1251 Avenue of the
Americas, New York, NY 10020 Attention: Allen Fisher Telephone: 212 782 6824
Facsimile: 212 782 6445

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

CITIBANK, N.A., as a “New Term Loan Lender” By:

    /s/ Laura Fogarty

Name: Laura Fogarty Title: Vice President Notice Address: 388 Greenwich Street,
Floor 32 New York, NY 10013 Attention: Laura Fogarty Telephone: 212 816 2197
Facsimile: 646 862 8137

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

DEUTSCHE BANK AG NEW YORK BRANCH, as a “New Term Loan Lender” By:

    /s/ Michael Winters

Name: Michael Winters Title: Vice President By:

    /s/ Peter Cucchiara

Name: Peter Cucchiara Title: Vice President Notice Address: Loan Admin 5022,
Gate Parkway, Suite 200 Jacksonville, FL 32256 Attention: Karthik Krishnan
Telephone: 904 520 5449 Facsimile: 866 240 3622

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer VALEANT
PHARMACEUTICALS INTERNATIONAL By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer BAUSCH &
LOMB INCORPORATED By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer
BAUSCH & LOMB HOLDINGS INCORPORATED By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Vice President and Treasurer SOLTA MEDICAL,
INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Vice President and Treasurer

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

ATON PHARMA, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer CORIA
LABORATORIES, LTD. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer DOW
PHARMACEUTICAL SCIENCES, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

OBAGI MEDICAL PRODUCTS, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Treasurer OMP, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Treasurer ONPHARMA INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Treasurer

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

Signed by Valeant Holdco 2 Pty Ltd (ACN 154 341 367) in accordance with
section 127 of the Corporations Act 2001 by two directors:

/s/ Robert R. Chai-Onn

/s/ Howard B. Schiller

Signature of director Signature of director

Robert R. Chai-Onn

Howard B. Schiller

Name of director (please print) Name of director (please print) Signed by Wirra
Holdings Pty Limited (ACN 122 216 577) in accordance with section 127 of the
Corporations Act 2001 by two directors:

/s/ Robert R. Chai-Onn

/s/ Howard B. Schiller

Signature of director Signature of director

Robert R. Chai-Onn

Howard B. Schiller

Name of director (please print) Name of director (please print) Signed by Wirra
Operations Pty Limited (ACN 122 250 088) in accordance with section 127 of the
Corporations Act 2001 by two directors:

/s/ Robert R. Chai-Onn

/s/ Howard B. Schiller

Signature of director Signature of director

Robert R. Chai-Onn

Howard B. Schiller

Name of director (please print) Name of director (please print)

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

Signed by

iNova Pharmaceuticals (Australia) Pty Limited

(ACN 000 222 408)

in accordance with section 127 of the Corporations Act 2001 by two directors:

/s/ Robert R. Chai-Onn

/s/ Howard B. Schiller

Signature of director Signature of director

Robert R. Chai-Onn

Howard B. Schiller

Name of director (please print) Name of director (please print) Signed by Wirra
IP Pty Limited (ACN 122 536 350) in accordance with section 127 of the
Corporations Act 2001 by two directors:

/s/ Robert R. Chai-Onn

/s/ Howard B. Schiller

Signature of director Signature of director

Robert R. Chai-Onn

Howard B. Schiller

Name of director (please print) Name of director (please print) Signed by iNova
Sub Pty Limited (ACN 134 398 815) in accordance with section 127 of the
Corporations Act 2001 by two directors:

/s/ Robert R. Chai-Onn

/s/ Howard B. Schiller

Signature of director Signature of director

Robert R. Chai-Onn

Howard B. Schiller

Name of director (please print) Name of director (please print)

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

Signed by

Valeant Pharmaceuticals Australasia Pty Limited

(ACN 001 083 352)

in accordance with section 127 of the Corporations Act 2001 by a director and
secretary/director:

/s/ Robert R. Chai-Onn

/s/ Linda A. LaGorga

Signature of director Signature of director/secretary

Robert R. Chai-Onn

Linda A. LaGorga

Name of director (please print) Name of director/secretary (please print) Signed
by DermaTech Pty Limited (ACN 003 982 161) in accordance with section 127 of the
Corporations Act 2001 by a director and secretary/director:

/s/ Robert R. Chai-Onn

/s/ Howard B. Schiller

Signature of director Signature of director/secretary

Robert R. Chai-Onn

Howard B. Schiller

Name of director (please print) Name of director/secretary (please print)

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

Signed by

Private Formula International Holdings Pty Ltd

(ACN 095 450 918)

in accordance with section 127 of the Corporations Act 2001 by a director and
secretary/director:

/s/ Robert R. Chai-Onn

/s/ Howard B. Schiller

Signature of director Signature of director/secretary

Robert R. Chai-Onn

Howard B. Schiller

Name of director (please print) Name of director/secretary (please print) Signed
by

Private Formula International Pty Ltd

(ACN 095 451 442)

in accordance with section 127 of the Corporations Act 2001 by a director and
secretary/director:

/s/ Robert R. Chai-Onn

/s/ Howard B. Schiller

Signature of director Signature of director/secretary

Robert R. Chai-Onn

Howard B. Schiller

Name of director (please print) Name of director/secretary (please print)

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

Signed by Ganehill Pty Ltd (ACN 065 261 538) in accordance with section 127 of
the Corporations Act 2001 by a director and secretary/director:

/s/ Robert R. Chai-Onn

/s/ Howard B. Schiller

Signature of director Signature of director/secretary

Robert R. Chai-Onn

Howard B. Schiller

Name of director (please print) Name of director/secretary (please print)

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

Signed by Bausch & Lomb (Australia) Pty Ltd (ACN: 000 650 251) in accordance
with section 127 of the Corporations Act 2001 by a director and
secretary/director:

/s/ Linda LaGorga

/s/ Ling Zeng

Signature of director Signature of director/secretary

Linda LaGorga

Ling Zeng

Name of director (please print) Name of director/secretary (please print)

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

HYTHE PROPERTY INCORPORATED By:

             /s/ Mauricio Zavala

Name:  Mauricio Zavala Title:    Manager and Assistant Secretary

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

VALEANT INTERNATIONAL BERMUDA

By:

             /s/ Graham Jackson

Name:  Graham Jackson Title:    Director VALEANT PHARMACEUTICALS NOMINEE BERMUDA
By:

             /s/ Peter McCurdy

Name:  Peter McCurdy Title:    President and Assistant Secretary

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

PROBIÓTICA LABORATÓRIOS LTDA. By:

             /s/ Marcelo Noll Barboza

Name:  Marcelo Noll Barboza Title:    Officer By:

             /s/ Guilherme Maradei

Name:  Guilherme Maradei Title:    Officer

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

IOLAB CORPORATION By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Treasurer TECHNOLAS PERFECT VISION, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer BAUSCH &
LOMB PHARMA HOLDINGS CORP. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer BAUSCH &
LOMB CHINA, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer BAUSCH &
LOMB SOUTH ASIA, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer BAUSCH &
LOMB TECHNOLOGY CORPORATION By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:     Treasurer

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

RHC HOLDINGS, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer SIGHT
SAVERS, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer BAUSCH &
LOMB INTERNATIONAL, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer BAUSCH &
LOMB REALTY CORPORATION. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Vice President and Treasurer ISTA
PHARMACEUTICALS, LLC By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer VRX
HOLDCO, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Chief Financial Officer and Treasurer

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

VALEANT CANADA GP LIMITED By:

             /s/ Howard B. Schiller

Name:  Howard B. Schiller Title:    Executive Vice President and Chief
             Financial Officer VALEANT CANADA S.E.C./VALEANT CANADA LP By:

             /s/ Howard B. Schiller

Name:  Howard B. Schiller Title:    Executive Vice President and Chief
             Financial Officer V-BAC HOLDING CORP. By:

             /s/ Robert R. Chai-Onn

Name:  Robert R. Chai-Onn Title:    Vice President

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

MEDICIS PHARMACEUTICAL CORPORATION By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer OCEANSIDE
PHARMACEUTICALS, INC. By:

             /s/ Howard B. Schiller

Name:  Howard B. Schiller Title:    Chief Financial Officer and Treasurer DR.
LEWINN’S PRIVATE FORMULA INTERNATIONAL, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer PRINCETON
PHARMA HOLDINGS, LLC By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer PRIVATE
FORMULA CORP. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer RENAUD
SKIN CARE LABORATORIES, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

VALEANT BIOMEDICALS, INC. By:

        /s/ Howard B. Schiller

Name: Howard B. Schiller Title: Chief Financial Officer and Treasurer VALEANT
PHARMACEUTICALS NORTH AMERICA LLC By:

        /s/ Linda A. LaGorga

Name: Linda A. LaGorga Title: Senior Vice President and Treasurer BIOVAIL
AMERICAS CORP. By:

        /s/ Howard B. Schiller

Name: Howard B. Schiller Title: Chief Financial Officer and Treasurer ORAPHARMA,
INC. By:

        /s/ Linda A. LaGorga

Name: Linda A. LaGorga Title: Senior Vice President and Treasurer ORAPHARMA
TOPCO HOLDINGS, INC. By:

        /s/ Linda A. LaGorga

Name: Linda A. LaGorga Title: Senior Vice President and Treasurer PRESTWICK
PHARMACEUTICALS, INC. By:

        /s/ Howard B. Schiller

Name: Howard B. Schiller Title: Chief Financial Officer and Treasurer

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

BIOVAIL INTERNATIONAL S.Á.R.L. By:

        /s/ Michael Kennan

Name: Michael Kennan Title: Manager VALEANT PHARMACEUTICALS LUXEMBOURG S.Á.R.L.
By:

        /s/ Michael Kennan

Name: Michael Kennan Title: Manager VALEANT INTERNATIONAL LUXEMBOURG S.Á.R.L.
By:

        /s/ Michael Kennan

Name: Michael Kennan Title: Manager BAUSCH & LOMB LUXEMBOURG S.Á.R.L. By:

        /s/ Michael Kennan

Name: Michael Kennan Title: Manager

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

LABORATOIRE CHAUVIN S.A.S. By:

        /s/ Linda A. LaGorga

Name: Linda A. LaGorga Title:   General Manager BAUSCH & LOMB FRANCE S.A.S. By:

        /s/ Linda A. LaGorga

Name: Linda A. LaGorga Title:   General Manager BCF S.A.S. By:

        /s/ Linda A. LaGorga

Name: Linda A. LaGorga Title:   General Manager CHAUVIN OPSIA S.A.S. By:

        /s/ Linda A. LaGorga

Name: Linda A. LaGorga Title:   General Manager

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

VALEANT PHARMA HUNGARY LLC By:

             /s/ István Langer

Name:  István Langer Title:    Managing Director VALEANT PHARMA HUNGARY LLC By:

             /s/ Zoltán Gábor

Name:  Zoltán Gábor Title:    Managing Director

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

VALEANT PHARMACEUTICALS IRELAND By:

             /s/ Graham Jackson

Name:  Graham Jackson Title:    Director VALEANT HOLDINGS IRELAND By:

             /s/ Graham Jackson

Name:  Graham Jackson Title:    Director

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

B.L.J. COMPANY, LTD. By:

             /s/ Ian Dolling

Name:  Ian Dolling Title:    Representative Director and President

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

AB SANITAS By:

             /s/ Saulius Mečislovas Žemaitis

Name:  Saulius Mečislovas Žemaitis Title:    General Manager

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

UCYCLYD PHARMA, INC. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Senior Vice President and Treasurer

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

VALEANT EUROPE B.V. By:

             /s/ Robert Meijer

Name:  Robert Meijer Title:    Attorney-in-Fact BAUSCH & LOMB B.V. By:

             /s/ Robert Meijer

Name:  Robert Meijer Title:    Attorney-in-Fact BAUSCH & LOMB OPS B.V. By:

             /s/ Robert Meijer

Name:  Robert Meijer Title:    Attorney-in-Fact

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

PRZEDSIĘBIORSTWO FARMACEUTYCZNE JELFA

S.A.

By:

             /s/ Marcin Wnukowski

Name:  Marcin Wnukowski Title:    Attorney-in-Fact VALEANT SP.Z O. O. By:

             /s/ Marcin Wnukowski

Name:  Marcin Wnukowski Title:    Attorney-in-Fact VP VALEANT SP. Z O.O.SP.J.
By:

             /s/ Marcin Wnukowski

Name:  Marcin Wnukowski Title:    Attorney-in-Fact VALEANT SPÓŁKA Z OGRANICZONĄ
ODPOWIEDZIALNOŚCIĄ SP.J. By:

             /s/ Marcin Wnukowski

Name:  Marcin Wnukowski Title:    Attorney-in-Fact

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

PHARMASWISS D.O.O., BEOGRAD By:

             /s/ Dejan Antonić

Name:  Dejan Antonić Title:    General Manager              (corporate stamp)

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

PHARMASWISS D.O.O., LJUBLJANA By:

             /s/ Senahil Asanagić

Name:  Senahil Asanagić Title:    Director

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

INOVA PHARMACEUTICALS PROPRIETARY LIMITED By:

             /s/ Howard B. Schiller

Name:  Howard B. Schiller Title:    Director

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

PHARMASWISS SA By:

             /s/ Matthias Courvoisier

Name:  Matthias Courvoisier Title:    Director

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

Executed by BAUSCH & LOMB U.K. LIMITED, acting by:

/s/ Linda A. LaGorga

Director

Name of director: Linda A. LaGorga

in the presence of:

/s/ Kaleena Nguyen

Name of witness: Kaleena Nguyen Address: 400 Somerset Corporate Blvd.
               Bridgewater, New Jersey 08807 U.S.A. Occupation: Legal

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

BAUSCH & LOMB IOM S.P.A. By:

             /s/ Linda A. LaGorga

Name:  Linda A. LaGorga Title:    Director

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

SIGNED for and on behalf ) of VALEANT PHARMACEUTICALS ) NEW ZEALAND LIMITED )
/s/ Howard Schiller /s/ Robert R. Chai-Onn Name:  Howard Schiller Name:  Robert
R. Chai-Onn Title:    Director Title:    Director

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

INOVA PHARMACEUTICALS (SINGAPORE) PTE LIMITED By:

             /s/ Howard Schiller

Name:  Howard Schiller Title:    Director

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

Consented to by: BARCLAYS BANK PLC As Administrative Agent and Collateral Agent
By:

        /s/ Christine Aharonian

        Authorized Signatory

 

[Signature Page to Joinder Agreement]

--------------------------------------------------------------------------------

SCHEDULE A

TO JOINDER AGREEMENT

 

Name of Lender

  

Type of Commitment

   Amount  

BARCLAYS BANK PLC

   Series A-3 Tranche A Term Loan Commitment    $ 43,355,063.29   

JPMORGAN CHASE BANK, N.A., TORONTO BRANCH

   Series A-3 Tranche A Term Loan Commitment    $ 13,815,361.55   

MORGAN STANLEY BANK, N.A.

   Series A-3 Tranche A Term Loan Commitment    $ 43,866,587.69   

THE BANK OF TOKYO-MITSUBISHI UFJ, LTD.

   Series A-3 Tranche A Term Loan Commitment    $ 37,784,395.23   

CITIBANK N.A.

   Series A-3 Tranche A Term Loan Commitment    $ 18,057,639.49   

DEUTSCHE BANK AG NEW YORK BRANCH

   Series A-3 Tranche A Term Loan Commitment    $ 74,703,025.70   

SUNTRUST BANK

   Series A-3 Tranche A Term Loan Commitment    $ 18,417,927.05         

 

 

  Total: $ 250,000,000